ANTI-RH(D) FOR THE TREATMENT OF HEPATITIS C ASSOCIATED IMMUNE THROMBOCYTOPENIA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary aims of this study are to assess the effectiveness and safety of Anti-RH (D) therapy in elevating platelet counts in Hepatitis C associated thrombocytopenia (a condition when platelets are abnormally low). It is anticipated that if a benefit is seen with Anti-Rh (D) in this patient group, a larger prospective randomized trial will be conducted to compare Anti-Rh (D) to other commonly used treatment modalities, such as corticosteroids or IVIg. Because of the problems with current treatment modalities and the lack of a true standard of care in these patients, prospective randomized studies await the determination of additional effective and well-tolerated therapies.